SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as the community discusses the potential impact of a recent deal with OpenAI, particularly regarding revenue projections and AMD's position relative to Nvidia. Some believe the deal validates AMD's technology and could drive the share price higher, while others express concerns about valuation and potential overbought conditions. The overall sentiment is bullish, with many anticipating further gains, though some caution a possible pullback is coming.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as the lock-up period expired, leading to a significant drop that some community members believe was overdone, presenting a "buy the dip" opportunity. Discussions revolve around a potential short squeeze, comparisons to similar plays like $HOOD, and the possibility of a reversal to previous levels. Some traders are also looking at options activity and technical indicators to determine potential price movements.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid discussions around a recent private placement and its potential impact on the stock's future. The community is debating whether this influx of capital will fuel growth or dilute shareholder value, with some highlighting the company's potential in the quantum computing sector while others express concerns about valuation and profitability. Technical analysis and potential government contracts are also being heavily discussed.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid volatility and debate over its valuation relative to revenue, with discussions focusing on potential catalysts like a possible upcoming offering. Community members are actively debating whether the stock's momentum can be sustained or if a significant pullback is imminent, especially in light of comparisons to other quantum computing companies and broader market conditions. The stock's high trading volume and rapid price appreciation have intensified the discussions.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors discuss its potential as a leader in AI-powered automation, particularly within the agentic economy. Bullish sentiment is fueled by recent partnerships with major players like Nvidia, OpenAI, and Google, sparking speculation about a possible breakout and short squeeze. The community highlights UiPath's strong fundamentals and undervaluation compared to other AI stocks, viewing it as a long-term growth opportunity.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending as traders discuss its low market cap relative to its cash reserves, speculating on potential buybacks or strategic moves. The community is watching for news catalysts, especially regarding potential cryptocurrency ventures, which could trigger a price surge. Some are comparing it to recent low-float bio stock runners, anticipating a similar breakout.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market rallies, fueled by optimism around potential rate cuts and continued AI hype, though some community members express concern about a possible bubble. Discussions revolve around the sustainability of the current pump, potential overvaluation, and the influence of government policies. The Invesco QQQ Trust is hitting new all-time highs, prompting debates about market manipulation and whether a significant pullback is on the horizon.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the idea of tokenizing Satoshi Nakamoto's legacy, calling it the 'BTC of memes'. Enthusiasts express strong conviction in its potential, emphasizing its cultural significance and branding within the crypto space. Many believe $SATOSHI embodies the ethos of the entire crypto industry.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amidst a debate over its valuation and long-term potential in the quantum computing sector. Bulls cite potential government contracts, big tech partnerships and the company's quantum supremacy as reasons for optimism, while bears point to high valuations and a new 2x short ETF ($QBTZ) as signs of a possible correction. Community members are actively discussing whether this surge is sustainable or a bubble about to burst.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to its recent contract news, which has sparked significant interest in the stock's potential. The community is actively discussing its low float and potential for a substantial run, while also noting the stock's volatility and trading patterns. Some traders believe the stock is undervalued, while others are wary of potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know 

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Equity

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts

Latest Ratings for OVID
 DateFirmActionFromTo Aug 2021CitigroupMaintainsNeutral Apr 2021Cantor FitzgeraldDowngradesOverweightNeutral Dec 2020CitigroupDowngradesBuyNeutral
 View More Analyst...

H.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics (OVID Research Report), with a price...

Buy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial Outlook

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today. Ritu Baral has given his Buy rating due t...

Buy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug Prospects

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics (OVID Research Report), retaining the price target of $3.00...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$1.58
Prev Close	$1.67
Open	$1.67
Dividend Yield	0.00%
50-Day Moving Average	$1.09
Beta	1.00
Avg. Volume	1.98M
PE Ratio	-3.11

52-Week High	$2.01
52-Week Low	$0.2425
Market Capitalization	$118.75M
EPS (Annual)	-$0.3728
Price to Book	2.13
Revenue Per Employee	$24,608.70
Enterprise Value/EBITDA	N/A

OVID
Ovid Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OVID News

OVID Ovid Therapeutics Inc